High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort.
暂无分享,去创建一个
D. Costagliola | N. Mounier | F. Raffi | O. Lambotte | M. Raphael | F. Bonnet | B. Marchou | J. Gabarre | P. Brice | C. Goujard | R. Costello | S. Prévôt | R. Lancar | Y. Taoufik | M. Partisani | C. Besson | S. Trabelsi | H. Hendel-Chavez | M. Meyohas | F. Boué | M. Algarte-Genin | L. Marchand | H. Hendel‐Chavez
[1] I. Krznaric,et al. Hodgkin lymphoma is as common as non‐Hodgkin lymphoma in HIV‐positive patients with sustained viral suppression and limited immune deficiency: a prospective cohort study , 2015, HIV medicine.
[2] J. Connors. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. , 2015, Blood.
[3] R. Little,et al. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. , 2015, Blood.
[4] J. Vose,et al. Prognostic factors for advanced‐stage human immunodeficiency virus‐associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi‐institutional retrospective study , 2015, Cancer.
[5] M. Hleyhel. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort , 2014, AIDS.
[6] Liron Pantanowitz,et al. Diagnosis and management of lymphomas and other cancers in HIV-infected patients , 2014, Nature Reviews Clinical Oncology.
[7] E. Engels,et al. Prevalence of HIV Infection among U.S. Hodgkin Lymphoma Cases , 2013, Cancer Epidemiology, Biomarkers & Prevention.
[8] D. Costagliola,et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] M. Mims,et al. Effect of Immune Reconstitution on the Incidence of HIV-Related Hodgkin Lymphoma , 2013, PloS one.
[10] Richard D Moore,et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. , 2013, Journal of the National Cancer Institute.
[11] J. Sterne,et al. Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. , 2012, International journal of epidemiology.
[12] J. Rockstroh,et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Gribben,et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Lazzarin,et al. Ten‐year survival among HIV‐1‐infected subjects with AIDS or non‐AIDS‐defining malignancies , 2012, International journal of cancer.
[15] K. Dunleavy,et al. How I treat HIV-associated lymphoma. , 2012, Blood.
[16] É. Oksenhendler,et al. The spectrum of malignancies in HIV‐infected patients in 2006 in France: The ONCOVIH study , 2011, International journal of cancer.
[17] J. Goedert,et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. , 2011, Blood.
[18] J. Goedert,et al. Cancer burden in the HIV-infected population in the United States. , 2011, Journal of the National Cancer Institute.
[19] S. Franceschi,et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study , 2010, British Journal of Cancer.
[20] J. Goedert,et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Guiguet,et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. , 2009, The Lancet. Oncology.
[22] S. Cole,et al. A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected Individuals , 2009, Journal of acquired immune deficiency syndromes.
[23] E. Cesarman,et al. HIV-associated lymphomas and gamma-herpesviruses. , 2009, Blood.
[24] N. Mizuki,et al. A mouse model of allogeneic corneal endothelial cell transplantation. , 2008, Cornea.
[25] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. López-Guillermo,et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. , 2007, Haematologica.
[27] R. Amini,et al. Bulky disease is the most important prognostic factor in Hodgkin lymphoma stage IIB , 2003, European journal of haematology.
[28] É. Oksenhendler,et al. Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy , 2003, AIDS.
[29] C. Katlama,et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. , 2001, Blood.
[30] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[31] J. Diebold,et al. Lymphomas associated with HIV infection. , 1997, Cancer surveys.